Chris Twelves

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Hennig Ivo M; Twelves Chris
Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills?
Haller Daniel G; Cassidy Jim; Clarke Stephen J; Cunningham David; Van Cutsem Eric; Hoff Paulo M; Rothenberg Mace L; Saltz Leonard B; Schmoll Hans-Joachim; Allegra Carmen; Bertino Joseph R; Douillard Jean-Yves; Gustavsson Bengt G; Milano Gerard; O'Connell Michael; Rustum Youcef; Tabernero Josep; Gilberg Frank; Sirzén Florin; Twelves Chris
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Clamp A R; Schöffski P; Valle J W; Wilson R H; Marreaud S; Govaerts A-S; Debois M; Lacombe D; Twelves C; Chick J; Jayson G C;
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Chris Twelves (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Hennig Ivo M; Twelves Chris
Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills?
European journal of cancer (Oxford, England : 1990) 2008;44(11):1493-6.
2008: Haller Daniel G; Cassidy Jim; Clarke Stephen J; Cunningham David; Van Cutsem Eric; Hoff Paulo M; Rothenberg Mace L; Saltz Leonard B; Schmoll Hans-Joachim; Allegra Carmen; Bertino Joseph R; Douillard Jean-Yves; Gustavsson Bengt G; Milano Gerard; O'Connell Michael; Rustum Youcef; Tabernero Josep; Gilberg Frank; Sirzén Florin; Twelves Chris
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2118-23.
2008: Clamp A R; Schöffski P; Valle J W; Wilson R H; Marreaud S; Govaerts A-S; Debois M; Lacombe D; Twelves C; Chick J; Jayson G C;
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2008;61(4):579-85.
2008: Twelves Chris
Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
Nature clinical practice. Oncology 2008;5(2):72-3.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Calvert Hilary; Boddy Alan V; Hollema Harry; Féty Regine; Van der Vijgh Wjf J F; Hempel Georg; Chatelut Etienne; Karlsson Mats; Wilkins Justin; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Christian; Beijnen Jos H; Schellens Jan H M
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Appleton Kim; Mackay Helen J; Judson Ian; Plumb Jane A; McCormick Carol; Strathdee Gordon; Lee Chooi; Barrett Sophie; Reade Sarah; Jadayel Dalal; Tang Adrian; Bellenger Katharine; Mackay Lynsay; Setanoians Albert; Schätzlein Andreas; Twelves Chris; Kaye Stanley B; Brown Robert
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4603-9.
2007: Scott L; Soepenberg O; Verweij J; de Jonge M J A; Th Planting A S; McGovern D; Principe P; Obach R; Twelves C
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):569-75.
2007: Benson C; White J; De Bono J; O'Donnell A; Raynaud F; Cruickshank C; McGrath H; Walton M; Workman P; Kaye S; Cassidy J; Gianella-Borradori A; Judson I; Twelves C
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
British journal of cancer 2007;96(1):29-37.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Féty Régine; de Bruijn Ernst; Hempel Georg; Karlsson Mats; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Chris; Beijnen Jos H; Schellens Jan H M;
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2006: Leonard R; O'Shaughnessy J; Vukelja S; Gorbounova V; Chan-Navarro C A; Maraninchi D; Barak-Wigler N; McKendrick J J; Harker W G; Bexon A S; Twelves C
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(9):1379-85.
2006: Ralph Lorraine D; Sandstrom Marie; Twelves Chris; Dobbs Nicola A; Thomson Alison H
Assessment of the validity of a population pharmacokinetic model for epirubicin.
British journal of clinical pharmacology 2006;62(1):47-55.
2006: Cassidy J; Douillard J-Y; Twelves C; McKendrick J J; Scheithauer W; Bustová I; Johnston P G; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan T S; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel K K; Cowell W; Garrison L P
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
British journal of cancer 2006;94(8):1122-9.
2006: Fiedler W; Tchen N; Bloch J; Fargeot P; Sorio R; Vermorken J B; Collette L; Lacombe D; Twelves C;
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
European journal of cancer (Oxford, England : 1990) 2006;42(2):200-4.
2005: Beutel Gernot; Glen Hilary; Schöffski Patrick; Chick Jon; Gill Stan; Cassidy James; Twelves Chris
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5487-95.
2005: Twelves Chris; Wong Alfred; Nowacki Marek P; Abt Markus; Burris Howard; Carrato Alfredo; Cassidy Jim; Cervantes Andrés; Fagerberg Jan; Georgoulias Vassilis; Husseini Fares; Jodrell Duncan; Koralewski Piotr; Kröning Hendrik; Maroun Jean; Marschner Norbert; McKendrick Joseph; Pawlicki Marek; Rosso Riccardo; Schüller Johannes; Seitz Jean-François; Stabuc Borut; Tujakowski Jerzy; Van Hazel Guy; Zaluski Jerzy; Scheithauer Werner
Capecitabine as adjuvant treatment for stage III colon cancer.
The New England journal of medicine 2005;352(26):2696-704.
2005: Verma Shailendra; Maraninchi Dominique; O'Shaughnessy Joyce; Jamieson Carol; Jones Stephen; Martín Miguel; McKendrick Joseph; Miles David; Twelves Chris; Hornberger John
Capecitabine plus docetaxel combination therapy.
Cancer 2005;103(12):2455-65.
2005: Ravaud Alain; Cerny Thomas; Terret Catherine; Wanders Jantien; Bui Binh Nguyen; Hess Dagmar; Droz Jean-Pierre; Fumoleau Pierre; Twelves Chris
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
European journal of cancer (Oxford, England : 1990) 2005;41(5):702-7.
2005: Eatock M; Cassidy J; Johnson J; Morrison R; Devlin M; Blackey R; Owen S; Choi L; Twelves C
A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
Cancer chemotherapy and pharmacology 2005;55(1):39-46.
2004: Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1816-24.
2004: Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S
Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
British journal of cancer 2004;91(9):1651-5.
2004: Salazar Ramon; Bissett Donald; Twelves Chris; Breimer Lars; DeMario Mark; Campbell Sophia; Zhi Jay; Ritland Steve; Cassidy Jim
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4374-82.
2004: Sparreboom Alex; Gelderblom Hans; Marsh Sharon; Ahluwalia Ranjeet; Obach Rosendo; Principe Paola; Twelves Chris; Verweij Jaap; McLeod Howard L
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Clinical pharmacology and therapeutics 2004;76(1):38-44.
2004: Bottomley Andrew; Biganzoli Laura; Cufer Tanja; Coleman Robert E; Coens Corneel; Efficace Fabio; Calvert Hilary Allan; Gamucci Teresa; Twelves Chris; Fargeot Pierre; Piccart Martine;
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2576-86.
2004: Bissett D; Cassidy J; de Bono J S; Muirhead F; Main M; Robson L; Fraier D; Magnè M L; Pellizzoni C; Porro M G; Spinelli R; Speed W; Twelves C
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT).
British journal of cancer 2004;91(1):50-5.
2004: Cassidy Jim; Tabernero Josep; Twelves Chris; Brunet René; Butts Charles; Conroy Thierry; Debraud Filippo; Figer Arie; Grossmann Johannes; Sawada Noriaki; Schöffski Patrick; Sobrero Alberto; Van Cutsem Eric; Díaz-Rubio Eduardo
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2084-91.
2004: Ralph Lorraine D; Thomson Alison H; Dobbs Nicola A; Twelves Chris
Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.
British journal of clinical pharmacology 2004;57(6):764-72.
2004: Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman R E; Calvert H A; Gamucci T; Twelves C; Fargeot P; Bottomley A;
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(7):1021-30.
2003: Scheithauer W; McKendrick J; Begbie S; Borner M; Burns W I; Burris H A; Cassidy J; Jodrell D; Koralewski P; Levine E L; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1735-43.
2003: Twelves Chris; Reck Martin; Anthoney Alan; Gatzemeier Ulrich; Kaye Stan
A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.
Cancer chemotherapy and pharmacology 2003;52(4):277-81.
2003: Gelderblom Hans; Salazar Ramon; Verweij Jaap; Pentheroudakis George; de Jonge Maja J A; Devlin Martin; van Hooije Christel; Seguy Francis; Obach Rosendo; Pruñonosa Joan; Principe Paola; Twelves Chris
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4101-7.
2003: Twelves C; Hoekman K; Bowman A; Vermorken J B; Anthoney A; Smyth J; van Kesteren C; Beijnen J H; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: Mackay H J; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham M A; Uzzel M; Bailey S M; Martin C; Cunningham D
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1264-9.
2003: Ralph Lorraine D; Thomson Alison H; Dobbs Nicola A; Twelves Chris
A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Cancer chemotherapy and pharmacology 2003;52(1):34-40.
2003: Propper D J; de Bono J; Saleem A; Ellard S; Flanagan E; Paul J; Ganesan T S; Talbot D C; Aboagye E O; Price P; Harris A L; Twelves C
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):203-10.
2002: Twelves Christopher
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Oncology (Williston Park, N.Y.) 2002;16(12 Suppl No 14):23-6.
2002: Pentheroudakis G; Twelves C
The rational development of capecitabine from the laboratory to the clinic.
Anticancer research 2002;22(6B):3589-96.
2002: Leonard R C F; Twelves C; Breddy J; Chaturvedi A; Hutcheon A; Salazar R; Cameron D
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
European journal of cancer (Oxford, England : 1990) 2002;38(15):2020-4.
2002: Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert A H; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart M J
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3114-21.
2002: O'Shaughnessy Joyce; Miles David; Vukelja Svetislava; Moiseyenko Vladimir; Ayoub Jean-Pierre; Cervantes Guadalupe; Fumoleau Pierre; Jones Stephen; Lui Wing-Yiu; Mauriac Louis; Twelves Chris; Van Hazel Guy; Verma Shailendra; Leonard Robert
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(12):2812-23.
2002: Pentheroudakis George; Twelves Chris
Capecitabine (Xeloda): from the laboratory to the patient's home.
Clinical colorectal cancer 2002;2(1):16-23.
2002: Twelves C; Campone M; Coudert B; Van den Bent M; de Jonge M; Dittrich C; Rampling R; Sorio R; Lacombe D; de Balincourt C; Fumoleau P;
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):777-80.
2002: Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky R L;
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):566-75.
2002: van Kesteren Charlotte; Twelves Chris; Bowman Angela; Hoekman Klaas; López-Lázaro Luis; Jimeno José; Guzman Cecilia; Mathôt Ron A A; Simpson Andrew; Vermorken Jan B; Smyth John; Schellens Jan H M; Hillebrand Michel J X; Rosing Hilde; Beijnen Jos H
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: Poole Christopher; Gardiner Jill; Twelves Chris; Johnston Patrick; Harper Peter; Cassidy Jim; Monkhouse Jayne; Banken Ludger; Weidekamm Erhard; Reigner Bruno
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Cancer chemotherapy and pharmacology 2002;49(3):225-34.
2002: Lacombe D; Fumoleau P; Zwierzina H; Twelves C; Hakansson L; Jayson G; Lehmann F; Verweij J;
The EORTC and drug development. European Organisation for Research and Treatment of Cancer.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S19-23.
2002: Biganzoli Laura; Martin Miguel; Twelves Chris
Moving forward with capecitabine: a glimpse of the future.
The oncologist 2002;7 Suppl 6():29-35.
2002: O'Shaughnessy Joyce; Twelves Chris; Aapro Matti
Treatment for anthracycline-pretreated metastatic breast cancer.
The oncologist 2002;7 Suppl 6():4-12.
2001: Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel W H; Seitz J F; Thompson P; Vieitez J M; Weitzel C; Harper P;
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4097-106.
2001: Jones R; Twelves C
Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?
Expert opinion on pharmacotherapy 2001;2(9):1495-505.
2001: Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
European journal of cancer (Oxford, England : 1990) 2001;37(5):597-604.
2001: Propper D J; McDonald A C; Man A; Thavasu P; Balkwill F; Braybrooke J P; Caponigro F; Graf P; Dutreix C; Blackie R; Kaye S B; Ganesan T S; Talbot D C; Harris A L; Twelves C
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1485-92.
2001: Twelves C
Vision of the future: capecitabine.
The oncologist 2001;6 Suppl 4():35-9.
2001: Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
Answering patients' needs: oral alternatives to intravenous therapy.
The oncologist 2001;6 Suppl 4():12-6.
2000: Twelves C; Anthoney A
Rational development of capecitabine.
Seminars in oncology 2000;27(5 Suppl 10):144-8.
2000: Pronk L C; Vasey P; Sparreboom A; Reigner B; Planting A S; Gordon R J; Osterwalder B; Verweij J; Twelves C
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
British journal of cancer 2000;83(1):22-9.
2000: Macleod U; Ross S; Twelves C; George W D; Gillis C; Watt G C
Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records.
BMJ (Clinical research ed.) 2000;320(7247):1442-5.
2000: Van Cutsem E; Findlay M; Osterwalder B; Kocha W; Dalley D; Pazdur R; Cassidy J; Dirix L; Twelves C; Allman D; Seitz J F; Schölmerich J; Burger H U; Verweij J
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1337-45.
2000: Macleod U; Ross S; Gillis C; McConnachie A; Twelves C; Watt G C
Socio-economic deprivation and stage of disease at presentation in women with breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):105-7.
1999: Thomson A H; Vasey P A; Murray L S; Cassidy J; Fraier D; Frigerio E; Twelves C
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
British journal of cancer 1999;81(1):99-107.
1999: Thavasu P; Propper D; McDonald A; Dobbs N; Ganesan T; Talbot D; Braybrook J; Caponigro F; Hutchison C; Twelves C; Man A; Fabbro D; Harris A; Balkwill F
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Cancer research 1999;59(16):3980-4.
1999: Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1696-702.
1999: Stevenson J P; DeMaria D; Sludden J; Kaye S B; Paz-Ares L; Grochow L B; McDonald A; Selinger K; Wissel P; O'Dwyer P J; Twelves C
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):339-44.
1999: Vasey P A; Kaye S B; Morrison R; Twelves C; Wilson P; Duncan R; Thomson A H; Murray L S; Hilditch T E; Murray T; Burtles S; Fraier D; Frigerio E; Cassidy J
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):83-94.
1999: Eatock M; Church N; Harris R; Angerson W; McArdle C; French R; Twelves C
Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule.
Investigational new drugs 1999;17(2):111-20.
1999: Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cancer chemotherapy and pharmacology 1999;44(6):453-60.
1999: Mackay H J; Bissett D; Twelves C; Vasey P A
A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1999;11(3):174-8.
1998: Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
British journal of cancer 1998;78(10):1329-36.
1998: Mackean M; Planting A; Twelves C; Schellens J; Allman D; Osterwalder B; Reigner B; Griffin T; Kaye S; Verweij J
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2977-85.
1998: Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):941-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Chris Twelves

Research Profile (preview)

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Chris Twelves (preview)

All Publications